Gpr177 as a Drug Target for Cancer Treatment
Inhibition of Gpr177 poses a therapeutic solution for disorders caused by aberrant Wnt signaling cascade, such as cancer. We would like to partner with AbbVie to advance this technology and ultimately identify therapeutic molecules to inhibit Gpr177 and treat cancers.